Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Flora Zagouri's publication output changed over time?
ScholarIQpublication output · 2009–2026
Output grew0% over the shown period — from 1 works in 2009 to 1 in 2026.
1
1
2
1
2
1
2
1
20092012201320192022202320242026
What are the most-cited papers on Flora Zagouri?
ScholarIQmost cited works
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron
New England Journal of Medicine. 20222,619 CitationsOPEN ACCESS
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva, Pier Ramos-Elías, Alejandro Acevedo, Vladyslav Sukhin, Noelle Cloven, Andrea Juliana Gomes, Fernando Contreras Mejía, Ari Reiss, Ali̇ Ayhan, Jung‐Yun Lee, Valeriya Saevets, Flora Zagouri, Lucy Gilbert, Jalid Sehouli, Ekkasit Tharavichitkul, Kristina Lindemann, Roberta Lazzari, Chih‐Long Chang, Rudolf Lampé, Hong Zhu, Ana Oaknin, Melissa Christiaens, Stephan Polterauer, Tomoka Usami, Kan Li, Karin Yamada, Sarper Toker, Stephen J. O’Keefe, Sandro Pignata, Linda Duska
The Lancet. 2024374 Citations
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Fabrice André, Yeon Hee Park, Sung‐Bae Kim, Toshimi Takano, Seock‐Ah Im, Giuliano Borges, João Paulo da Silveira Nogueira Lima, Sercan Aksoy, Joaquín Gavilá Gregori, Michelino De Laurentiis, Giampaolo Bianchini, Rebecca Roylance, Yasuo Miyoshi, Anne Armstrong, Rajni Sinha, Manuel Ruíz Borrego, Elgene Lim, Johannes Ettl, Rinat Yerushalmi, Flora Zagouri, François P. Duhoux, Tanja Fehm, Dhiraj Gambhire, Jillian Cathcart, Wu Cai, Changan Chu, Anton Egorov, Ian E. Krop
The Lancet. 2023358 CitationsOPEN ACCESS
Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting
Frédéric Amant, Paul Berveiller, Ingrid Boere, Elyce Cardonick, Robert Fruscio, Monica Fumagalli, M Halaška, Annette Hasenburg, Anna L.V. Johansson, Matteo Lambertini, Christianne Lok, Charlotte Maggen, Philippe Morice, Fedro A. Peccatori, Pieter Jan Poortmans, Kristel Van Calsteren, Tineke Vandenbroucke, Mathilde van Gerwen, Marry van den Heuvel‐Eibrink, Flora Zagouri, Ignacio Zapardiel
Annals of Oncology. 2019283 CitationsOPEN ACCESS
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva, Pier Ramos-Elías, Alejandro Acevedo, Jakub Cvek, Leslie M. Randall, Andrea Juliana Gomes, Fernando Contreras Mejía, Limor Helpman, Hüseyin Akıllı, Jung‐Yun Lee, Valeriya Saevets, Flora Zagouri, Lucy Gilbert, Jalid Sehouli, Ekkasit Tharavichitkul, Kristina Lindemann, Nicoletta Colombo, Chih‐Long Chang, Markéta Bednaříková, Hong Zhu, Ana Oaknin, Melissa Christiaens, Edgar Petru, Tomoka Usami, Peng Liu, Karin Yamada, Sarper Toker, Stephen J. O’Keefe, Sandro Pignata, Linda Duska
The Lancet. 2024177 Citations
Related on ScholarIQ
National and Kapodistrian University of Athens
Institution
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Paper
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Paper
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Paper
Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting
Paper
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Paper